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Liﬁtegrast Ophthalmic Solution 5.0% versus
Placebo for Treatment of Dry Eye Disease
Results of the Randomized Phase III OPUS-2 Study
Joseph Tauber, MD,1 Paul Karpecki, OD,2 Robert Latkany, MD,3 Jodi Luchs, MD,4 Joseph Martel, MD,5
Kenneth Sall, MD,6 Aparna Raychaudhuri, PhD,7 Valerie Smith, MBA,7 Charles P. Semba, MD,7 for the
OPUS-2 Investigators*
Purpose: Liﬁtegrast is an integrin antagonist that decreases T-cellemediated inﬂammation associated with
dry eye disease (DED). We report the results of OPUS-2, a phase III study evaluating the efﬁcacy and safety of
liﬁtegrast compared with placebo for the treatment of DED.
Design: A 12-week, multicenter, randomized, prospective, double-masked, placebo-controlled clinical trial.
Participants: Adults aged 18 years with use of artiﬁcial tears within 30 days, inferior corneal staining
score 0.5 (0e4 scale), Schirmer tear test (without anesthesia) 1 and 10 mm, and eye dryness score 40
(0e100 visual analogue scale [VAS]).
Methods: Subjects were randomized 1:1 after 14-day placebo run-in to liﬁtegrast ophthalmic solution 5.0%
or placebo twice daily for 84 days.
Main Outcome Measures: Co-primary efﬁcacy end points were change, from baseline to day 84, in eye
dryness score (VAS, both eyes) and inferior corneal ﬂuorescein staining score in the designated study eye.
Secondary end points were change, from baseline to day 84, in ocular discomfort score (0e4 scale) in study eye,
eye discomfort score (VAS), total corneal staining score in the study eye, and nasal conjunctival lissamine green
staining score (0e4 scale) in the study eye. Treatment-emergent adverse events (TEAEs) were recorded.
Results: A total of 718 subjects were randomized: placebo, n ¼ 360; liﬁtegrast, n ¼ 358 (intent-to-treat
population). Liﬁtegrast-treated subjects experienced greater improvement in eye dryness than placebo-treated
subjects (treatment effect, 12.61; 95% conﬁdence interval [CI], 8.51e16.70; P < 0.0001). There was no
between-group difference in inferior corneal staining (treatment effect, 0.03; 95% CI, 0.10 to 0.17; P ¼ 0.6186).
There was nominally signiﬁcant improvement of secondary symptom end points among liﬁtegrast-treated subjects: ocular discomfort (nominal P ¼ 0.0005) and eye discomfort (nominal, P < 0.0001). There were no betweengroup differences on secondary signs: total corneal staining and nasal lissamine staining. More liﬁtegrast-treated
subjects (33.7%) than placebo-treated subjects (16.4%) experienced ocular TEAEs; no ocular TEAEs were
serious.
Conclusions: Liﬁtegrast met the co-primary symptom end point (eye dryness) but not the co-primary sign
end point (inferior corneal staining). Secondary end point ﬁndings were consistent with this pattern. Most ocular
TEAEs were mild to moderate; there were no unexpected TEAEs. Liﬁtegrast warrants further consideration as a
treatment for DED. Ophthalmology 2015;122:2423-2431 ª 2015 by the American Academy of Ophthalmology. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
*Supplemental material is available at www.aaojournal.org.

Dry eye disease (DED) is characterized by symptoms of eye
dryness and discomfort and associated ocular surface
inﬂammation.1 Traditional treatment approaches in DED
have typically included artiﬁcial tear substitutes, lubricant
gels and ointments, nutritional supplements, topical
cyclosporine, corticosteroids, and punctal plugs. However,
many patients with DED continue to experience symptoms
despite treatment.1
Liﬁtegrast is a novel small-molecule integrin antagonist
that blocks the interaction between intercellular adhesion
molecule 1 and lymphocyte functional antigen 1, inhibiting
T-cell adhesion, migration, activation, and subsequent
 2015 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.

cytokine release and thereby decreasing T-cellemediated
inﬂammation known to be associated with DED.2e4 In a
phase III study (OPUS-1), liﬁtegrast ophthalmic solution
5.0% administered twice daily for 84 days signiﬁcantly
reduced inferior corneal staining score, the prespeciﬁed
co-primary end point, compared with placebo.5 However,
there was no signiﬁcant difference between groups in the
co-primary symptom end point, change on the visualrelated function subscale of a symptom scale.
No minimum visual-related subscale score was required
for OPUS-1 eligibility, and baseline symptom severity was
relatively mild.5 Evaluation of the OPUS-1 results led to
http://dx.doi.org/10.1016/j.ophtha.2015.08.001
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modiﬁcations in the design of OPUS-2, including removing
the use of a controlled adverse environment (CAE)6 as a
screening method, requiring a minimal threshold of
disease severity at baseline on the symptom co-primary
end point measure, and requiring recent use of artiﬁcial
tears. In addition, on the basis of the reliability and sensitivity of the eye dryness score (visual analog scale [VAS])
measure in OPUS-1, eye dryness was chosen as the coprimary symptom end point in OPUS-2.
This report presents the results of the OPUS-2 study
evaluating the efﬁcacy and safety of liﬁtegrast ophthalmic
solution 5.0% compared with placebo in the treatment of
DED. Efﬁcacy was assessed by the co-primary end points of
change, from baseline to day 84, in eye dryness score and
inferior corneal ﬂuorescein staining score.

Methods
This was a 12-week, phase III, multicenter, randomized, prospective, double-masked, placebo-controlled, parallel-arm study conducted in the United States (31 sites; 30 sites randomized subjects).
The study was Health Insurance Portability and Accountability Act
compliant and adhered to the tenets of the Declaration of Helsinki.
Ethics committee approval was obtained before study initiation. All
subjects provided written informed consent. The trial was registered at ClinicalTrials.gov (identiﬁer NCT01743729).

Subjects
All study sites were community eye clinics in the United States.
Study participants were identiﬁed through study sites’ patient databases or through recruiting/advertising.
Eligible participants were adults (aged 18 years) who had
self-reported history of DED, use of artiﬁcial tears within the past
30 days, best-corrected visual acuity of 0.7 logarithm of the minimum angle of resolution or better, corneal ﬂuorescein staining
score 2 (0e4 point scale) in 1 eye region, conjunctival redness
score 1 (0e4 point scale) in 1 eye, eye dryness score 40 (0- to
100-point VAS) reported as a single score for both eyes, and
positive response in 1 eye, deﬁned as meeting the following
criteria in the same eye at both visits 1 and 2: inferior corneal
ﬂuorescein staining score 0.5 and Schirmer tear test (without
anesthesia) 1 and 10 mm. Subjects with secondary Sjögren’s
syndrome were eligible to participate if they were not taking systemic/ocular steroids, were not immunodeﬁcient/immunosuppressed, and met all other inclusion and exclusion criteria.
The following individuals were excluded from participation in
the study: women who were pregnant or might become pregnant;

Figure 1. Study design.
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those with contraindications or hypersensitivity to the investigational product, previous liﬁtegrast therapy, use of topical medications or antibiotics for treatment of blepharitis or meibomian gland
disease, ocular herpes, ocular infection within the previous 30
days, blood donation or loss within the previous 56 days, ocular
conditions or chronic illness that could affect study parameters, a
disorder causing immunodeﬁciency, a history of LASIK or similar
surgery within the previous 12 months, history of
yttriumealuminumegarnet laser posterior capsulotomy within the
previous 6 months, or known history of alcohol or drug abuse that
might interfere with study participation; those unwilling to discontinue wearing contact lenses during the study period; those
using prohibited medications, including topical cyclosporine, any
other ophthalmic medication, antihistamines, and aspirin during the
prestudy washout period and study; and those with DED secondary
to scarring or destruction of conjunctival goblet cells.

Study Protocol
The investigational product was supplied as a sterile solution
containing 5.0% liﬁtegrast with w0.2 ml in each unit dose vial.
Trained study personnel administered the study drug and performed assessments. Ocular assessments such as staining procedures were performed by trained study physicians.
Subjects were randomly assigned to receive liﬁtegrast or placebo on the basis of a 1:1 ratio within the randomization strata
using permuted blocks. Randomization was centralized across
study centers and stratiﬁed by baseline inferior corneal ﬂuorescein
staining score in the study eye and baseline eye dryness score. An
interactive Web response system was used to facilitate subject
randomization.
During the screening period (days 14 to 0), subjects received
twice-daily open-label placebo administered as a single eye drop in
both eyes (Fig 1).
During the treatment period (days 0e84), subjects received
twice-daily doses of liﬁtegrast ophthalmic solution 5.0% or placebo
administered to the ocular surface as a single eye drop (in the
morning and just before bedtime in the evening) in each eye. All
study personnel were masked with regard to treatment assignments.
Investigational product packaging was standardized such that liﬁtegrast and placebo were visually indistinguishable. No subjects
were unmasked during the study.
Site staff administered the ﬁrst dose of randomized investigational product on day 0 and a dose at each subsequent scheduled
visit in the morning. Subjects self-administered the investigational
product for all other doses. Treatment compliance was assessed by
reconciliation of used and unused investigational product vials
collected from subjects. Noncompliance was recorded as a protocol
deviation if >20% of expected doses since the last visit were
missed or >120% of expected doses were taken.
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During the washout and treatment periods, subjects were prohibited from using topical cyclosporine or any other ophthalmic
medication, including artiﬁcial tears.

Outcome Measures
Efﬁcacy parameters were assessed at each study visit (visit 1,
day 14; visit 2, day 0; visit 3, day 14; visit 4, day 42; and visit 5,
day 84). These included corneal ﬂuorescein staining (0 ¼ no
staining, 4 ¼ severe; 0.5-point increments; in the superior, central,
and inferior corneal zones), conjunctival lissamine green staining
(0 ¼ no staining, 4 ¼ severe; 0.5-point increments), VAS (a 7-item,
subject-reported symptom index [0e100 scale; 0 ¼ no discomfort,
100 ¼ maximal discomfort] that includes items for eye dryness and
eye discomfort), and ocular discomfort graded by the subject
(0 ¼ no discomfort, 4 ¼ severe discomfort). For each subject, the
eye with the worst (highest) inferior corneal ﬂuorescein staining
score at day 14 and day 0 was designated the study eye.
The co-primary efﬁcacy end points were the eye dryness score
(VAS, reported as a single score for both eyes) measured by mean
change from baseline to day 84 and inferior corneal ﬂuorescein
staining score measured by mean change from baseline to day 84 in
the designated study eye.
The secondary efﬁcacy end points were change, from baseline
to day 84, in ocular discomfort score in the designated study eye;
eye discomfort score (VAS, reported as a single score for both
eyes); total corneal staining score (derived sum of superior, central,
and inferior corneal ﬂuorescein staining scores; 0e12 points) in the
designated study eye; and nasal conjunctival lissamine green
staining score in the designated study eye.
Adverse events (AEs) recorded after the ﬁrst randomized dose
of investigational product were considered treatment-emergent
adverse events (TEAEs). The investigators assessed adverse
events for severity (mild, moderate, and severe).

Statistical Methods
Sample size was calculated as follows: for the primary ocular
symptom, change in eye dryness score, a 10.0-unit difference between treatment groups in mean change from baseline to day 84
and a common standard deviation (SD) of 40 units were assumed
on the basis of ﬁndings from the previous phase III trial.5 For the
primary ocular sign, change in inferior corneal staining, a 0.25-unit
difference, and a common SD of 0.95 units, were assumed, again
on the basis of earlier study ﬁndings. Under both assumptions, a
sample size of 350 per group would yield >90% power to show a
signiﬁcant difference at the a ¼ 0.05 level under a 2-sample t test.
The randomized population included all randomized subjects.
The intent-to-treat (ITT) population and the safety population
included all randomized subjects who received 1 dose of investigational product. The ITT population was the primary efﬁcacy
analysis population. Analyses conducted using the ITT population
were based on treatment assigned, whereas analyses conducted
using the safety population were based on treatment received.
For efﬁcacy data, subjects were analyzed on observed data or
last observation carried forward (LOCF). For analyses based on
LOCF, data were taken from the last post-baseline date that data
were collected.
For co-primary efﬁcacy end points, each analysis was performed
using a stratiﬁed 2-sample t test (using an analysis of variance
[ANOVA] model) comparing liﬁtegrast with placebo in the ITT
population with LOCF. The ANOVA model included treatment,
strata, and the interaction between treatment and strata. The stratiﬁed
2-sample t test was done in PROC MIXED in SAS (SAS Institute
Inc, Cary, NC) via the LSMEANS statement with the observed
margins (OM) option and weights proportional to stratum sample

size. Statistical signiﬁcance was required for both co-primary end
points to test the secondary end points. Therefore, no adjustment for
multiplicity was necessary for the co-primary end points.
Secondary efﬁcacy end points were analyzed using the same
ANOVA model as for the co-primary efﬁcacy end points. Hochberg’s procedure was applied to control the type I error rate at the
5% level across all secondary end points.
The incidence of ocular and nonocular TEAEs was tabulated by
treatment group, system organ class, and preferred term (Medical
Dictionary for Regulatory Activities version 14.1; MedDRA
MSSO, McLean, VA).
The original study protocol was amended once on September 6,
2013. The study objectives and efﬁcacy outcome measures were
updated to clarify that they would be measured in the designated
study eye, where appropriate, and be measured as the change from
baseline to day 84 rather than as the day 84 score.

Results
Subject Disposition
A total of 1455 subjects were screened, representing 1450 unique
subjects (Fig 2). Of the screened subjects, 557 did not enter the
placebo run-in period because of screening failure, and a further
178 subjects were not randomized after the placebo run-in period
because of screening failure.
The remaining 718 subjects were randomized, 360 to placebo
and 358 to liﬁtegrast (ITT population). Data from each of these
subjects were included in the efﬁcacy analysis. A total of 49
subjects (12 in the placebo group and 37 in the liﬁtegrast group)
discontinued treatment before day 84, so their data were analyzed
via LOCF.
A total of 27 subjects, 13 in the placebo group and 14 in the
liﬁtegrast group, were randomized but later found to not have
met all inclusion/exclusion criteria, primarily because washout
dates of previous medications could not be conﬁrmed. All of these
subjects were assessed by the sponsor and allowed to continue
participation in the study, and they were included in the study
analyses.
One subject was assigned to the placebo group but received
liﬁtegrast via an incorrect kit at day 14 and was discontinued from
the study. This subject was included in the liﬁtegrast group for the
safety population, but in the placebo group for the randomized and
ITT populations.
The ﬁrst subject was randomized on December 20, 2012, and
the last subject’s last visit was on October 1, 2013.

Baseline Characteristics
Baseline characteristics were similar between treatment groups
(Table 1). Subjects’ ages ranged from 19 to 97 years, with a mean
(SD) age of 58.8 (14.09) years. The majority of subjects were
female, not Hispanic or Latino, and white. The most common
iris colors were brown and blue.
The mean (SD) inferior corneal staining score at baseline was
2.40 (0.722) in the placebo group and 2.39 (0.763) in the liﬁtegrast
group. The mean (SD) eye dryness score at baseline was 69.22
(16.761) in the placebo group and 69.68 (16.954) in the liﬁtegrast
group. To promote balance of treatment assignment across baseline
severity, randomization was stratiﬁed by inferior corneal ﬂuorescein staining score (1.5 or >1.5) and eye dryness score
(<60 or 60) in the study eye (Table 2). Most subjects (57.0%)
had an inferior corneal ﬂuorescein staining score >1.5 and an
eye dryness score 60 at randomization.
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Figure 2. Participant ﬂow. The total screening count of 1455 subjects includes 1450 unique subjects. One subject was assigned to the placebo group, but
received liﬁtegrast via an incorrect kit at day 14 and was discontinued from the study. This subject was included in the liﬁtegrast group for the safety
population (placebo, 359; liﬁtegrast, 359), but in the placebo group for the randomized and intent-to-treat populations (placebo, 360; liﬁtegrast, 358).
LOCF ¼ last observation carried forward.

All subjects had an ocular medical history of DED (the primary
diagnosis). Other than the primary diagnosis, the most common
(>10%) occurrences in ocular medical history were cataract
(35.0%), cataract operation (14.9%), blepharitis (11.3%), and
LASIK (10.9%). Within nonocular medical history, the most
common (>10%) occurrences were hypertension (37.9%), postmenopause (29.4%), hysterectomy (19.8%), gastroesophageal
reﬂux disease (17.3%), menopause (15.6%), hypothyroidism
(15.5%), depression (14.5%), drug hypersensitivity (14.3%), hypercholesterolemia (12.0%), and hyperlipidemia (10.4%).
Overall, 5.2% of subjects took concomitant medications for
ocular health, most commonly ﬁsh oil with minerals or vitamins
(1.0% of subjects). Most (83.8%) subjects took concomitant nonocular medications, most commonly acetylsalicylic acid, vitamins,

2426

cholecalciferol, and ﬁsh oil. The proportions of subjects using
particular concomitant medications were generally similar between
treatment groups.
On the basis of investigational product vials returned, 95.5% of
placebo-treated subjects and 93.0% of liﬁtegrast-treated subjects
were compliant with study treatment.

Efﬁcacy Findings
For the co-primary efﬁcacy end point of eye dryness (VAS), the
mean (SD) change from baseline to day 84 with LOCF was 22.75
(28.600) among placebo-treated subjects and 35.30 (28.400)
among liﬁtegrast-treated subjects. The treatment effect was 12.61
(95% conﬁdence interval [CI], 8.51e16.70; P < 0.0001) (Fig 3).
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Table 1. Demographics of Randomized Population
Characteristic

Placebo
(n [ 360)

Liﬁtegrast
(n [ 358)

All Subjects
(N [ 718)

Age (yrs)
Mean (SD)
58.9 (14.26) 58.7 (13.93) 58.8 (14.09)
75 yrs old, n (%)
42 (11.7)
39 (10.9)
81 (11.3)
Female sex, n (%)
265 (73.6)
285 (79.6)
550 (76.6)
Hispanic or Latino ethnicity,
64 (17.8)
79 (22.1)
143 (19.9)
n (%)
Race, n (%)
Asian
14 (3.9)
19 (5.3)
33 (4.6)
Black or African American
34 (9.4)
30 (8.4)
64 (8.9)
White
305 (84.7)
303 (84.6)
608 (84.7)
Other
7 (1.9)
6 (1.7)
13 (1.8)
SD ¼ standard deviation.
Percentages are based on the number of subjects randomized.

For the co-primary efﬁcacy end point of inferior corneal
staining, placebo-treated subjects had mean (SD) change from
baseline of 0.71 (0.943) compared with 0.73 (0.926) among
liﬁtegrast-treated subjects. No between-group difference was
observed (treatment effect, 0.03; 95% CI, 0.10 to 0.17; P ¼
0.6186).
A post hoc analysis based on the ITT population with observed
data found that the treatment effect for eye dryness at day 14 was
6.67 (95% CI, 3.05e10.30; nominal P ¼ 0.0003) and at day 42
was 10.63 (95% CI, 6.71e14.55; nominal P < 0.0001).
Per the statistical methodology of the study (described in the
“Methods” section), statistical signiﬁcance cannot be declared for
the secondary end points because only 1 of the co-primary end
point ﬁndings is statistically signiﬁcant. Therefore, P values reported for hypothesis testing of secondary efﬁcacy end points are
referred to as nominal P values.
The mean (SD) change in ocular discomfort score from baseline
to day 84 with LOCF was 0.57 (1.354) among placebo-treated
subjects and 0.91 (1.280) among liﬁtegrast-treated subjects.
The treatment effect was 0.34 (95% CI, 0.15e0.53; nominal
P ¼ 0.0005) (Fig 4).
For eye discomfort score (VAS), placebo-treated subjects had
mean (SD) change from baseline of 16.73 (31.207) compared
with 26.46 (31.238) among liﬁtegrast-treated subjects. The
treatment effect was 9.77 (95% CI, 5.27e14.28; nominal P <
0.0001).
The mean (SD) change in total corneal ﬂuorescein staining
score from baseline to day 84 was 1.49 (2.097) among placebotreated subjects and 1.62 (2.043) among liﬁtegrast-treated subjects. The treatment effect was 0.14 (95% CI, 0.16 to 0.44;
nominal P ¼ 0.3711).
For nasal lissamine staining score, placebo-treated subjects had
mean (SD) change from baseline of 0.27 (0.805) compared
Table 2. Number of Subjects in Randomization Strata
(Randomized Population)
Inferior Corneal
Score at Baseline
1.5
>1.5

Eye Dryness
Score at Baseline
<60
60
<60
60

Placebo
(n [ 360),
n (%)

Liﬁtegrast
(n [ 358),
n (%)

23
29
99
209

23
31
100
204

(6.4)
(8.1)
(27.5)
(58.1)

(6.4)
(8.7)
(27.9)
(57.0)

with 0.25 (0.850) among liﬁtegrast-treated subjects. The treatment effect was 0.02 (95% CI, 0.14 to 0.10; nominal P ¼
0.6982).

Safety Findings
The mean (SD) duration of treatment was similar between treatment groups (placebo, 82.1 [8.79] days; liﬁtegrast, 78.2 [17.87]
days).
A higher percentage of subjects in the liﬁtegrast group experienced TEAEs and ocular TEAEs than in the placebo group
(Table 3). The liﬁtegrast group had a higher frequency of subjects
with ocular TEAEs considered possibly or probably related to the
investigational product (11.1% and 17.3%, respectively) than the
placebo group (7.8% and 2.5%, respectively).
A total of 29 subjects had TEAEs that led to treatment
discontinuation; 26 of these were in the liﬁtegrast group. The most
common ocular TEAEs that led to treatment discontinuation were
instillation site irritation (n ¼ 5), eye irritation (n ¼ 4), and blepharitis (n ¼ 3).
Seven subjects had serious TEAEs (placebo, n ¼ 4; liﬁtegrast,
n ¼ 3), all of which were considered not related to the investigational product and resolved (except bladder cancer [placebo group]
with an unknown outcome). No serious ocular TEAEs occurred
during the study.
The most common TEAEs were reduced visual acuity, instillation site irritation (burning), instillation site reaction, and dysgeusia (change in taste sensation) (Table 4). Incidence of all
recorded ocular TEAEs is reported in Table 5, and incidence of
all nonocular TEAEs is reported in Table 6 (available at
www.aaojournal.org).
Except for visual acuity reduced, all of these TEAEs were
considered possibly or probably related to the investigation product
by the investigator.
Most of the ocular and nonocular TEAEs in both treatment
groups were mild to moderate in severity. Six subjects had ocular
TEAEs considered severe, all in the liﬁtegrast group: instillation
site irritation (n ¼ 2), eye irritation (n ¼ 3), and instillation site
reaction (n ¼ 1).
Overall, 41 subjects (placebo, n ¼ 23; liﬁtegrast, n ¼ 18) had an
ocular TEAE of reduced visual acuity, 12 subjects (placebo, n ¼ 2;
liﬁtegrast, n ¼ 10) had an ocular TEAE of blurred vision, and 1
subject (liﬁtegrast) had an ocular TEAE of visual impairment. All
of these TEAEs were nonserious, and 4 of the TEAEs led to
treatment discontinuation: visual acuity reduced (n ¼ 2) and vision
blurred (n ¼ 2).

Discussion
Dry eye disease is a symptomatic disorder associated with
chronic ocular surface inﬂammation. The OPUS-2 evaluated liﬁtegrast ophthalmic solution 5.0%, a novel investigational integrin antagonist. in improving the symptoms
and signs of DED when administered topically twice daily
for 12 weeks. The OPUS-2 demonstrated that liﬁtegrasttreated subjects experienced signiﬁcantly greater improvement in subject-reported eye dryness compared with
placebo-treated subjects. These ﬁndings were supported by
similar outcomes for ocular discomfort and eye discomfort.
To our knowledge, this is the ﬁrst pivotal study to meet
the prespeciﬁed symptom end points in a population
with DED.
In a post hoc analysis of OPUS-2 data, the treatment
beneﬁt of liﬁtegrast over placebo for the symptom
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Figure 3. Co-primary efﬁcacy end point results (intent-to-treat population). Graphs show observed data and end point with last observation carried forward
(LOCF). SE ¼ standard error.

co-primary efﬁcacy end point, eye dryness score, was
observed at day 14, the ﬁrst post-treatment visit, and steadily
increased until the last visit at day 84. A longer-term study is
warranted to evaluate the potential for prolonged beneﬁts
beyond 12 weeks.

We believe the subjective outcomes in OPUS-2 are
highly clinically relevant. On the basis of prior dry eye
surveys conducted with the Dry Eye Questionnaire, dryness
and discomfort tend to be the most consistent and worst
symptoms reported by patients with DED; this served as the

Figure 4. Secondary efﬁcacy end point results (intent-to-treat population). Graphs show observed data and end point with last observation carried forward
(LOCF). SE ¼ standard error.
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Table 3. Incidence of Treatment-Emergent Adverse Events (Safety Population)
Placebo (n [ 359), n (%)
Subjects with 1 ocular or nonocular TEAE
Ocular TEAEs
Mild
Moderate
Severe
Nonocular TEAEs
Mild
Moderate
Severe
Subjects with possibly or probably drug-related TEAEs
Ocular TEAEs
Mild
Moderate
Severe
Nonocular TEAEs
Mild
Moderate
Severe
Subjects prematurely withdrawn because of TEAEs
Ocular TEAEs
Nonocular TEAEs
Subjects with serious TEAEs
Ocular TEAEs
Nonocular TEAEs
Subjects with a TEAE resulting in death

92
59
47
12
0
45
28
14
3
41
37
28
9
0
6
5
1
0
3
2
1
4
0
4
0

(25.6)
(16.4)
(13.1)
(3.3)
(0)
(12.5)
(7.8)
(3.9)
(0.8)
(11.4)
(10.3)
(7.8)
(2.5)
(0)
(1.7)
(1.4)
(0.3)
(0)
(0.8)
(0.6)
(0.3)
(1.1)
(0)
(1.1)
(0)

Liﬁtegrast (n [ 359), n (%)
172
121
84
31
6
96
53
35
8
142
102
67
30
5
70
39
28
3
26
23
6
3
0
3
0

(47.9)
(33.7)
(23.4)
(8.6)
(1.7)
(26.7)
(14.8)
(9.7)
(2.2)
(39.6)
(28.4)
(18.7)
(8.4)
(1.4)
(19.5)
(10.9)
(7.8)
(0.8)
(7.2)
(6.4)
(1.7)
(0.8)
(0)
(0.8)
(0)

All Subjects (N [ 718), n (%)
264
180
131
43
6
141
81
49
11
183
139
95
39
5
76
44
29
3
29
25
7
7
0
7
0

(36.8)
(25.1)
(18.2)
(6.0)
(0.8)
(19.6)
(11.3)
(6.8)
(1.5)
(25.5)
(19.4)
(13.2)
(5.4)
(0.7)
(10.6)
(6.1)
(4.0)
(0.4)
(4.0)
(3.5)
(1.0)
(1.0)
(0)
(1.0)
(0)

Treatment-emergent adverse events (TEAEs) are deﬁned as adverse events that occur after the start of randomized treatment; worst severity used if a subject
had multiple adverse events in a group. Subjects were counted once per category per treatment. Medical Dictionary for Regulatory Activities version 14.1.

scientiﬁc rationale for the selection of the subjective end
points in OPUS-2.7e10 Furthermore, the symptomatic
treatment beneﬁt observed with liﬁtegrast was replicated
across 2 different psychometric instruments, the VAS
(which measures holistic impressions in response to the
prompted term) and the ocular discomfort score (which
measures the symptom in the speciﬁc study eye), suggesting
a consistent and broad response. Because subjects were
prohibited from using any other ophthalmic medication,
including artiﬁcial tears, during the course of the study, the
signiﬁcant improvement in symptoms can be attributed
directly to treatment with liﬁtegrast.
Although OPUS-2 met its symptom co-primary
end point, subjects treated with liﬁtegrast, compared with
those receiving placebo, did not demonstrate signiﬁcant

reductions in inferior corneal staining or conjunctival
staining parameters, outcomes that were observed in the
prior OPUS-1.5 In that study, liﬁtegrast-treated subjects had
greater improvement in inferior corneal staining score than
placebo-treated subjects (P ¼ 0.0007).5 However, OPUS-1
did not meet the symptom co-primary end point. The
disparity of the observed outcomes between the 2 studies is
likely due to several factors, including but not limited to the
multifactorial nature of DED, differences in experimental
conditions and subject selection criteria, and, most important, the discordance of signs and symptoms in DED both in
severity and in response to treatment.
The overall design of OPUS-2 was similar to that of
OPUS-15 with 3 main exceptions. First, in OPUS-1, subjects
were screened using a CAE,6 whereas in OPUS-2, subjects

Table 4. Summary of Most Frequent (>5%) Treatment-Emergent Adverse Events (Safety Population)
System Organ Class Preferred Term
Subjects with 1 ocular TEAE
Eye disorders
Reduced visual acuity
General disorders and administration site conditions
Instillation site irritation
Instillation site reaction
Subjects with 1 nonocular TEAE
Nervous system disorders
Dysgeusia

Placebo (n [ 359), n (%)
59
47
23
11
5
4
45
11
1

(16.4)
(13.1)
(6.4)
(3.1)
(1.4)
(1.1)
(12.5)
(3.1)
(0.3)

Liﬁtegrast (n [ 359), n (%)
121
85
18
57
28
25
96
63
58

(33.7)
(23.7)
(5.0)
(15.9)
(7.8)
(7.0)
(26.7)
(17.5)
(16.2)

All Subjects (N [ 718), n (%)
180
132
41
68
33
29
141
74
59

(25.1)
(18.4)
(5.7)
(9.5)
(4.6)
(4.0)
(19.6)
(10.3)
(8.2)

TEAE ¼ treatment-emergent adverse event. Medical Dictionary for Regulatory Activities version 14.1.
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were screened in the natural environment. Second, OPUS-1
did not require a minimum severity of the co-primary
symptom end point for enrollment, whereas OPUS-2
required a minimum eye dryness score 40 at baseline.
The combination of the use of CAE and no preset symptom
threshold resulted in OPUS-1 enrolling subjects with dynamic ocular signs and mild to moderate symptoms. Third,
in OPUS-2, subjects were required to have recent use of
artiﬁcial tears, which increased the probability of enrolling
subjects who were more symptomatic. As a result of these
differences, OPUS-2 enrolled subjects with moderate to
severe symptoms as assessed by baseline inferior corneal
staining scores (OPUS-2, 2.40 points; OPUS-1, 1.83 points)
and eye dryness scores (OPUS-2, 69.45 points; OPUS-1,
40.9 points),5 using a general deﬁnition of mild to
moderate of <2.0 points (4-point scale) for corneal staining and 40 points on the VAS (0e100 scale).
There may be a biological basis for the observed outcomes for the corneal staining end point in OPUS-2. For
subjects with advanced corneal staining at baseline, there
may be underlying corneal epithelial defects that increase
the difﬁculty of demonstrating liﬁtegrast treatment response,
whereas the drug response is readily observed in lessdiseased corneas where there is sufﬁcient capacity for
epithelial repair and recovery in the presence of liﬁtegrast.
In addition, the use of artiﬁcial tears, a requirement for
enrollment in OPUS-2, may have reduced the prevalence of
minor damages in corneal epithelium, making an effect
during the study more difﬁcult to detect.11,12
The vast amount of data generated by the liﬁtegrast
clinical studies provide further evidence that signs and
symptoms function independently rather than interdependently.13 This lack of interdependency remains the core
issue that has plagued DED researchers over the past 2
decades using co-primary end point study designs.
The safety proﬁle of liﬁtegrast observed in OPUS-2 was
similar to that in earlier clinical studies of liﬁtegrast.5,14 The
most commonly reported TEAEs associated with liﬁtegrast
were ocular instillation site symptoms (e.g., irritation) and
dysgeusia (e.g., abnormal taste). Most ocular TEAEs were
mild to moderate in severity, and there were no unexpected
or unanticipated AEs. There were no reported ocular or
drug-related serious TEAEs. There was no evidence of any
localized ocular or systemic immunosuppressive complications. Overall, liﬁtegrast seemed to be well tolerated when
administered twice daily for 12 weeks in this study.

Study Limitations
Limitations of OPUS-2 included selecting only subjects
actively using artiﬁcial tears, limiting treatment duration to
12 weeks, and excluding subjects with known active lid
margin disease. The rationale to limit subject selection to
active artiﬁcial tear users was based on the assumption that
subjects with signiﬁcant DED symptomatology were more
likely to be using artiﬁcial tears than subjects not actively
using artiﬁcial tears. However, this is arguably an imprecise
indicator of active DED because subjects may use artiﬁcial
tears for reasons other than DED,15,16 and conversely, the
study may have excluded subjects with advanced DED who
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have given up using or never used artiﬁcial tears on a
routine basis.13 Efﬁcacy outcomes for liﬁtegrast beyond 12
weeks have not been evaluated. Given that DED is a chronic
condition and may require long-term use of medication,
additional long-term studies are necessary. Finally, the study
population comprised primarily subjects with aqueousdeﬁcient DED and speciﬁcally excluded subjects with
active lid margin disease. Although many subjects with
DED have mixed components of both lid margin disease
and aqueous-deﬁcient DED, the role of liﬁtegrast in managing the inﬂammatory component of predominately meibomian gland disease has not yet been evaluated.
In conclusion, OPUS-2 demonstrated that liﬁtegrast
ophthalmic solution 5.0% signiﬁcantly improved symptoms
of eye dryness in subjects treated twice daily for 12 weeks
compared with placebo. In combination with earlier studies
showing that liﬁtegrast decreases corneal epitheliopathy,5,14
liﬁtegrast holds promise as a novel integrin antagonist for
the treatment of both signs and symptoms of DED and
warrants additional investigation.
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